United Arab Emirates
+919284790021

'investigational code pt1411'

Items tagged with 'investigational code pt1411'

product image
Sexual & Reproductive Health Peptide

Contact Us on telegram or WhatsApp ‪+917887449821‬ ‪+919168783773‬ ‪+919529672584‬ ‪+917499402610‬ Mail :- skyblueinternational033@gmail.com internationalskyblue@gmail.com Viwe our catalog :- https://www.skyblueinternationals.com/ Generic Name Bremelanotide 1. Hypoactive Sexual Desire Disorder (HSDD) in Women FDA-approved in 2019 under the brand Vyleesi for pre-menopausal women with generalized HSDD unrelated to other medical or psychological condition Improves sexual desire, arousal, and reduces distress linked to low libido 2. Erectile Dysfunction (ED) in Men (Off‑Label) PT‑141 initiates erections via central nervous system pathways, increasing sexual desire and erection quality—even in men unresponsive to PDE‑5 inhibitors Demonstrated increased duration and rigidity of erections in trials 3. Sexual Arousal Support Boosts libido in both genders, addresses low sexual drive and arousal disorders, potentially enhancing orgasm quality and reducing refractory time Bremelanotide is a 7 amino acid peptide used to treat hypoactive sexual desire disorder in premenopausal women. Bremelanotide does not interact with alcohol. The mechanism by which bremelanotide's action on receptors translates to a clinical effect is still unknown. Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.1 Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women.1,2,5 Other drugs used to treat female sexual dysfunction include flibanserin, estrogen, ospemifene, and prasterone. Bremelanotide was granted FDA approval Bremelanotide is an agonist of many melanocortin receptors which in order of potency are MC1R, MC4R, MC3R, MC5R, and MC2R.5 The mechanism by which agonism of these receptors translates to an improvement in hypoactive sexual desire disorder is currently unknown, however MC4R receptors are present in many areas of the central nervous system. MC3R and MC4R are found in the hypothalamus and are involved in food intake and energy homeostasis. Bremelanotide is a 7 amino acid and so its metabolism consists of multiple hydrolysis reactions.

Send Message
product image
Sexual & Reproductive Health Peptides

Contact Us on telegram or WhatsApp ‪+917887449821‬ ‪+919168783773‬ ‪+919529672584‬ ‪+917499402610‬ Mail :- skyblueinternational033@gmail.com internationalskyblue@gmail.com Viwe our catalog :- https://www.skyblueinternationals.com/ 🍼 Reproductive Health Stimulates uterine contractions during labor and supports milk ejection in breastfeeding. Oxytocin 10mg Boosts trust, empathy, and strengthens interpersonal connection Investigational in treating autism, social anxiety, depression, and PTSD via intranasal delivery. Reduces cortisol levels, improves stress resilience, relaxation, and mood balance. Lowers blood pressure, reduces inflammation, and shows anti-sepsis potential. Promotes wound healing, tissue repair, and pain relief. Reproductive roles (labor, lactation) Emotional and social behavior modulation Stress, mood, and mental health interventions Tissue healing and pain relief Metabolic enhancements (weight, glucose) Sexual and intimacy functions Administration & Dosage :- Injectable (subcutaneous/intramuscular): Used in reproductive health and healing research; dosages vary widely based on study protocols . we export in USA we export in UK we export in SINGAORE we export in AUSTRALIA we export in CHAINA we export in CANADA WORLD WIDE SHIPPING IN BEST DEALS..

Send Message
product image
Metabolic & Weight Management Peptides

Retatrutide 16mg is being developed to target multiple metabolic conditions, with its primary uses in obesity management, type 2 diabetes, and fatty liver disease. Retatrutide is an investigational triple hormone receptor agonist (GLP-1, GIP, and glucagon receptors) Main Uses of Retatrutide 1. Obesity Treatment Primary target: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition. Effectiveness: Up to 24.2% body weight loss at the highest tested dose (12 mg) over 48 weeks. Outperformed semaglutide (Wegovy) and tirzepatide (Zepbound) in trials. Mechanism: Appetite suppression Slowed gastric emptying Increased energy expenditure Type 2 Diabetes Management Improves blood glucose control by: Enhancing insulin sensitivity Increasing insulin secretion Reducing glucagon levels (in a glucose-dependent way) Massive reductions in liver fat (up to 82.4% in some patients) Helps improve: Liver enzyme profiles (ALT, AST) Hepatic insulin resistance SKYBLUE INTERNATIONAL is a trusted global pharmaceutical export company specializing in the export of high-quality medicines. With a strong commitment to healthcare excellence, we supply a wide range of branded and generic medicines to countries including the USA, UK, Australia, UAE, Canada, Singapore, and the Philippines. Our focus is on reliability, compliance, and timely delivery to meet the global demand for affordable and effective medical solutions. Medicine 💊 Retatrutide (16mg) BUY FROM SKYBLUE INTERNATIONAL Weight reduction Improved insulin sensitivity Hormonal balancing

Send Message
product image
Metabolic & Weight Management Peptides

Retatrutide (10mg) USA FAST DELIVERY Retatrutide (10mg : - Obesity and Overweight Management Retatrutide has demonstrated significant efficacy in promoting weight loss. In clinical trials, participants have achieved up to 24.2% weight loss over 48 weeks, outperforming existing treatments like semaglutide and tirzepatide. Form: Subcutaneous injection (once weekly) Dose Titration: To reduce side effects (especially GI issues), dosing typically starts low and increases over time. What Is Retatrutide Used For? Retatrutide is being developed to target multiple metabolic conditions, with its primary uses in obesity management, type 2 diabetes, and fatty liver disease. Retatrutide activates the GIP, GLP-1 and glucagon receptors that are involved with controlling hunger and satiety, allowing people to feel fuller after eating for longer. This helps to regulate blood sugar levels, leading to weight loss. Non-Alcoholic Fatty Liver Disease (NAFLD) Retatrutide has led to significant reductions in liver fat in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with reductions up to 82.4% observed in clinical trials. Target Population Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities (e.g., type 2 diabetes, hypertension) Adults with type 2 diabetes, especially those who need better weight and glucose control EXPORT FROM INDIA IN CHEAPEST PRICE. Retatrutide is an investigational drug still in clinical trials and has not yet been approved by the FDA for general use. However, based on Phase 2 clinical trials.

Send Message

Still searching for
investigational code pt1411?